Abiraterone acetate [250 mg tablet] in combination with prednisone as first-line or second-line treatment of metastatic castration-resistant prostate cancer (mCRPC)
General Track – Pre-Cycle 1 | DrugsHTA Council Recommendation (as of 23 November 2022)
The HTA Council recommends the government financing of abiraterone acetate (250mg tablet) in combination with prednisone (PD) as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC) through its inclusion in the Philippine National Formulary.
Relevant Information
- Status: With Final HTA Council Recommendation
- Topic Assignment: Internal Assessment
- Policy Question: Should abiraterone acetate (250 mg per tablet), in combination with prednisone, be included in the Philippine National Formulary for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)?
- Secretary of Health Decision: Approved as of 06 December 2022
Evidence and Relevant Documents